Top Page
BrainChip Holdings
(OTC:BRN)
BrainChip Holdings (BRN) vs. iShares MSCI Australia ETF (EWA)
BrainChip Holdings Business Overview & Revenue Model
BrainChip Holdings Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.95M | 398.01K | 232.00K | 5.07M | 1.59M |
| Gross Profit | -2.59M | -134.91K | 91.44K | 4.59M | 1.30M |
| EBITDA | -19.53M | -23.67M | -27.99M | -21.41M | -20.65M |
| Net Income | -21.18M | -24.43M | -28.88M | -22.09M | -20.98M |
Balance Sheet | |||||
| Total Assets | 34.17M | 23.05M | 20.18M | 29.18M | 23.78M |
| Cash, Cash Equivalents and Short-Term Investments | 31.73M | 20.00M | 14.34M | 23.12M | 19.37M |
| Total Debt | 1.18M | 1.17M | 1.70M | 2.05M | 1.85M |
| Total Liabilities | 3.46M | 3.22M | 3.35M | 5.46M | 4.84M |
| Stockholders Equity | 30.71M | 19.83M | 16.83M | 23.72M | 18.94M |
Cash Flow | |||||
| Free Cash Flow | -16.02M | -15.96M | -17.66M | -19.88M | -13.94M |
| Operating Cash Flow | -15.98M | -15.88M | -17.53M | -19.69M | -13.69M |
| Investing Cash Flow | -2.09M | -72.65K | -132.60K | -127.22K | -265.55K |
| Financing Cash Flow | 29.38M | 22.60M | 8.84M | 17.59M | 14.69M |
BrainChip Holdings Technical Analysis
BrainChip Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$54.60M | 15.13 | 10.79% | 4.66% | 14.59% | -11.13% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | AU$987.04M | -21.53 | -50.48% | ― | 333.23% | 10.83% | |
48 Neutral | AU$312.35M | -9.33 | -149.70% | ― | 503.29% | 11.46% | |
43 Neutral | AU$26.79M | -3.51 | -112.59% | ― | ― | -67.74% | |
37 Underperform | AU$181.10M | -14.84 | ― | ― | -100.00% | 44.26% |
BrainChip Holdings Corporate Events
BrainChip Holdings’ board has introduced a more disciplined investor relations framework aimed at improving transparency, consistency, and compliance with ASX continuous disclosure rules. The company is consolidating all external communications under a single board-approved policy and reducing informal channels in favor of structured, official disclosures.
The updated policy clarifies that BrainChip will focus announcements on price-sensitive information, binding contracts, material operational updates, and board-directed clarifications, while avoiding early-stage discussions and unverified projections. To keep investors better informed between major milestones, the company will add quarterly commercial progress summaries, interactive briefings with live Q&A, and standardized protocols for handling shareholder inquiries, reinforcing market integrity and equal access to information.
These changes signal a stronger governance stance that may bolster investor confidence and trust in the reliability of BrainChip’s market communications. The emphasis on global messaging consistency and prohibition of selective disclosure is designed to protect market integrity and support a more engaged and well-informed shareholder base.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings has lodged its updated corporate governance statement for the financial year ended 31 December 2025, confirming that the document is available on its investor website and has been approved by the board as of 18 February 2026. The filing, made via an Appendix 4G with the ASX, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, providing investors with greater transparency on board oversight, management accountability, and governance practices that underpin its operations.
The Appendix 4G also serves as a guide to where specific governance disclosures can be found and acts as a verification tool showing the company has met ASX disclosure requirements. By formally documenting its governance framework, including board charters, appointment processes and accountability of the company secretary, BrainChip reinforces its compliance credentials and supports shareholder confidence in its governance as it pursues growth in the AI technology sector.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip posted a sharp rise in revenue from continuing operations to US$1.89 million for the year to 31 December 2025, up 374% on the prior year, while narrowing its operating loss to US$21.71 million and after-tax loss to US$20.47 million. Results were supported by a swing to a US$1.31 million net finance and fair value gain, including foreign exchange and fair value movements, while loss per share improved and net tangible assets per share rose to 1.33 U.S. cents, even as the company maintained its no-dividend policy and reported an unqualified audit opinion.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip’s December 2025 quarter was marked by steady early-stage commercial traction and a strengthened balance sheet as it pushes to scale its neuromorphic AI platform. Customer cash inflows rose slightly to US$0.4 million while operating outflows fell to US$4.3 million, and the company bolstered liquidity to US$31.7 million following a fully underwritten A$35 million institutional placement and an oversubscribed share purchase plan, positioning it to fund commercialisation of its Akida technology and next-generation edge AI products. Operationally, BrainChip advanced a strategic multi-year partnership with Parsons’ Blue Ridge Envisioneering, including an initial 10,000-chip order and a supply framework geared to high-volume defence deployments, and it commenced volume production of its AKD1500 edge AI co-processor, which has been designed into solutions for defence and medical sensing and received a further order from Nex Novus. The AKD1500’s ultra-low power performance, compatibility with x86, ARM and RISC-V systems, and support for on-chip learning via BrainChip’s MetaTF toolchain and Akida architecture reinforce the company’s bid to capture share in the growing edge AI market, supported by an expanding portfolio of 61 issued and pending patents that enhances its competitive positioning.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings has notified the market of the issue of 879,061 new fully paid ordinary shares following the conversion or exercise of previously unquoted options or other convertible securities. The additional shares, effective from 10 November 2025, modestly increase the company’s share base and reflect the uptake of equity-based instruments, which may slightly dilute existing shareholders while providing the company with potential capital and aligning incentives for option or security holders.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings Ltd has notified the market that 1,666,190 restricted stock units (RSUs) under the ASX security code BRNAM have lapsed after the conditions attached to those securities were not met or became incapable of being satisfied as of 3 October 2025. The cessation of these conditional equity rights reduces the company’s potential future share issuance, marginally limiting dilution for existing shareholders and slightly tightening BrainChip’s issued capital structure, though with no immediate operational impact disclosed in the filing.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings Ltd announced the oversubscription of its Share Purchase Plan (SPP) by approximately $0.977 million, resulting in the issuance of an additional 5,581,714 shares. This move reflects strong investor interest and confidence in the company’s growth prospects, potentially strengthening its market position and providing additional capital for strategic initiatives.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings Ltd has announced the application for the quotation of 11,428,571 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, indicating a strategic step to enhance the company’s financial positioning and market presence. The issuance of these securities could potentially impact the company’s operational capabilities and offer new opportunities for stakeholders.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings Ltd announced the successful closure of its Share Purchase Plan, which exceeded the original target by $0.976 million, highlighting strong shareholder interest. The additional funds will support the company’s strategic initiatives, complementing a recent $35 million placement to institutional investors, and will be allocated as outlined in the SPP Booklet.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings Ltd announced the issuance of 300,000 restricted stock units as part of an employee incentive scheme. This move is likely aimed at retaining talent and aligning employee interests with company growth, potentially impacting the company’s operational efficiency and market competitiveness.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.